Tomas Kucera

Dr. Tomas Kucera

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2016 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
TKTomas Kucera
Tomas Kucera
HSHaroun Hassan Shaikh
Haroun Hassan Shaikh
PSPavel Sponer
Pavel Sponer
Charcot neuropathic osteoarthropathy of the foot is a relatively common complication of diabetic neuropathy. Incorrect diagnosis and improper treatment often result in the extremity having to be amputated. This paper summarises the current view on the etiology, diagnostics, and treatment of diabetic Charcot neuropathic osteoarthropathy, with particular focus on preserving the extremity through surgical intervention from our own experiences.

19 September 2014 in Skeletal Radiology
Verified
Journal Article
Closed access
PDF file
TKTomas Kucera
Tomas Kucera
JBJindra Brtkova
Jindra Brtkova
PSPavel Sponer
Pavel Sponer
LRLenka Ryskova
Lenka Ryskova
EPEduard Popper
Eduard Popper
MKMarie Kucerova
Marie Kucerova

6 November 2010 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
TKTomas Kucera
Tomas Kucera
KUKarel Urban
Karel Urban
PSPavel Sponer
Pavel Sponer

18 May 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
ESEva Snejdrova
Eva Snejdrova
JLJan Loskot
Jan Loskot
JMJuraj Martiska
Juraj Martiska
TSTomáš Soukup
Tomáš Soukup
LPLibor Prokes
Libor Prokes
TKTomas Kucera
Tomas Kucera

7 April 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
PSPavel Sponer
Pavel Sponer
SFStanislav Filip
Stanislav Filip
TKTomas Kucera
Tomas Kucera
JBJindra Brtková
Jindra Brtková
KUKarel Urban
Karel Urban
ESEva Syková
Eva Syková
The purpose of this prospective controlled study was to compare healing quality following the implantation of ultraporousβ-tricalcium phosphate, containing either expanded autologous mesenchymal stromal cells (trial group, 9 patients) orβ-tricalcium phosphate alone (control group, 9 patients), into femoral defects during revision total hip arthroplasty. Both groups were assessed using the Harris Hip Score, radiography, and DEXA scanning at 6 weeks and 3, 6, and 12 months postoperatively. A significant difference in the bone defect healing was observed between both groups of patients (P<0.05). In the trial group, trabecular remodeling was found in all nine patients and in the control group, in 1 patient only. Whereas, over the 12-month follow-up period, no significant difference was observed between both groups of patients in terms of the resorption ofβ-tricalcium phosphate, the significant differences were documented in the presence of radiolucency and bone trabeculation through the defect (P<0.05). Using autologous mesenchymal stromal cells combined with aβ-tricalcium phosphate scaffold is a feasible, safe, and effective approach for management of bone defects with compromised microenvironment. The clinical trial was registered at the EU Clinical Trials Register before patient recruitment has begun (EudraCT number2012-005599-33).

20 April 2020 in Journal of Natural Products
Verified
Journal Article
Closed access
JMJana Maříková
Jana Maříková
ARAneta Ritomská
Aneta Ritomská
Jan KorabecnyJan Korabecny
Jan Korabecny
RPRozálie Peřinová
Rozálie Peřinová
AMAbdullah Al Mamun
Abdullah Al Mamun
Lucie CahlikovaLucie Cahlikova
Lucie Cahlikova